3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Stomach Neoplasms
12
Carcinoma, Hepatocellular
6
Adenocarcinoma
6
Neoplasms
5
Lung Neoplasms
4
Colorectal Neoplasms
4
Colonic Neoplasms
4
Breast Neoplasms
4
Urethral Neoplasms
3
Rectal Neoplasms
3
Neoplasm Metastasis
3
Liver Neoplasms
3
Carcinoma, Renal Cell
3
Urinary Bladder Neoplasms
2
Ureteral Neoplasms
2
Solid Tumors
2
Sarcoma
2
Non-small Cell Lung Cancer Metastatic
2
Malignant Solid Tumor
2
Esophageal Neoplasms
2
Carcinoma, Transitional Cell
2
Biliary Tract Neoplasms
2
Thymoma
1
Solid Tumor
1
Sarcoma, Synovial
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Interventions
Radiotherapy
22
Fluorouracil
20
Oxaliplatin
19
Leucovorin
14
Cisplatin
14
Paclitaxel
10
Radiation
8
Irinotecan
8
Docetaxel
7
Capecitabine
7
Cetuximab
6
Carboplatin
6
pembrolizumab
5
Neoadjuvant Therapy
5
Trastuzumab
4
Taxes
4
Chemotherapy, Adjuvant
4
Panitumumab
3
Microarray Analysis
3
Immunohistochemistry
3
Folfox protocol
3
Epirubicin
3
Biopsy
3
tucatinib
2
Surgical Procedures, Operative
2
Reverse Transcriptase Polymerase Chain Reaction
2
Magnetic Resonance Spectroscopy
2
Gene Expression Profiling
2
Gefitinib
2
Everolimus
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Adenocarcinoma Of Esophagus
×
Ramucirumab
×
Clear all
NCT04499924
2025-01-22
MOUNTAINEER-02
Seagen Inc.
Phase 2/3
Completed
17 enrolled
23 charts